5 results about "TRPM8" patented technology

The present invention provides a method for effectively reducing corneal fluorescein staining (CFS) or improving corneal health, which includes administering a therapeutically effective amount of a TRPM8 agonist to a subject in need thereof, wherein the TRPM8 agonist comprises a DIPA compound (e.g., DIPA-9). The novel therapeutic use of the TRPM8 formulations according to the present invention may demonstrate improved efficacy through reduced CFS or SANDE.

The application belongs to the technical field of medicine preparation, and particularly relates to a TRPM8 agonist compound and a preparation method and application thereof. The deuterated TRPM8 agonist compound provided by the application has excellent TRPM8 receptor agonist activity, can effectively improve the symptoms of dry eye, significantly promote tear secretion and repair corneal epithelial damage, and has better curative effect than existing classical TRPM8 agonists, and can be used for preparing a medicine for treating dry eye, thereby providing a new effective selection for clinical treatment of dry eye. The deuterated TRPM8 agonist compound provided by the application is prepared by using a four-step synthesis process, raw materials are easy to obtain, process operation is simple, and the reaction process is stable and controllable, and is suitable for industrialized synthesis.

This specification describes modified monoterpene TRPM8 activating compounds. In particular, the compounds provided herein affect the function of ion channels in cells and are useful as therapeutic agents or in conjunction with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions, including inflammatory eye diseases such as uveitis, cardiovascular diseases, inflammatory diseases, and diseases characterized by abnormal growth such as cancer. This specification describes Ca 2+ This is an N-substituted C6 cyclylcarboxamide compound that affects intracellular ion transport, such as ions, and is useful as a therapeutic agent or in combination with one or more additional therapeutic agents.

The application provides a cannabinoid compound, a preparation method and application thereof. The cannabinoid compound has a structure shown in formula (I). The application obtains the cannabinoid compound with the novel structure through an artificial synthesis method, and finds that the cannabinoid compound has a selective inhibitory effect on a TRPM8 channel, so that a theoretical basis and a material basis are provided for further development of the cannabinoid compound as a potential drug.

A beverage is a drinkable liquid. Described here is a beverage containing a cooling agent that will exert cooling sensations in the upper center of the chest and make a subject feel comfortable. The cooling agent is an agent that targets TRPM8 receptors on nerve cell membranes. The beverage can be imbibed without unpleasant taste and the goal is to make the whole body feel cooler for about 20 min or more after drinking. By choosing the right molecule and right concentration, cooling intensity, location, and duration in the chest is controlled. Surprisingly, the cooling agent was also effective when consumed with warm or hot beverages. The beverage contains selected 1-diisopropyl-phosphinoyl-alkanes and taste-modulating agents selected from sweeteners, extracts from hops, ginger, or cinchona. Various uses of this cooling beverage are proposed.